Genomma Lab Internacional, S.A.B. de C.V.
GNMLFOTCHealthcare● Active
$0.95
$-0.13(-12.04%)
Market Cap$928865018
P/E Ratio—
52W High$1.17
52W Low$0.91
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GNMLF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 22, 2026EPS Actual
$0.03
Est. $0.03 · +6.5%
Revenue
$0.23B
Est. $0.23B · -0.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 22, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
GNMLF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 22, 2026 | $0.03 | — | — | — | $0.24B | — |
| ▲ Q2 FY2026 | Apr 22, 2026 | $0.03 | $0.03 | +6.5% | $0.23B | $0.23B | -0.5% |
| ▼ Q1 FY2026 | Feb 25, 2026 | $0.02 | $0.02 | -17.9% | $0.22B | $0.23B | -4.3% |
| ▼ Q4 FY2025 | Oct 23, 2025 | $0.03 | $0.02 | -13.7% | $0.24B | $0.25B | -3.6% |
| ▼ Q3 FY2025 | Jul 22, 2025 | $0.03 | $0.00 | -96.3% | $0.01B | $0.25B | -94.7% |
| ▲ Q2 FY2025 | Apr 30, 2025 | $0.02 | $0.02 | +19.8% | $0.21B | $0.24B | -9.9% |
| ▼ Q1 FY2025 | Feb 27, 2025 | $0.03 | $0.02 | -17.2% | $0.22B | $0.23B | -3.0% |
| ▼ Q4 FY2024 | Oct 23, 2024 | $0.03 | $0.00 | -93.4% | $0.26B | $0.24B | +9.7% |
Q3 FY2026
Jul 22, 2026
EPS Actual
—
EPS Est.
$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 22, 2026Beat
EPS Actual
$0.03
EPS Est.
$0.03
EPS Surpr.
+6.5%
Revenue
$0.23B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
$0.02
EPS Est.
$0.02
EPS Surpr.
-17.9%
Revenue
$0.22B
Q4 FY2025
Oct 23, 2025Miss
EPS Actual
$0.02
EPS Est.
$0.03
EPS Surpr.
-13.7%
Revenue
$0.24B
Q3 FY2025
Jul 22, 2025Miss
EPS Actual
$0.00
EPS Est.
$0.03
EPS Surpr.
-96.3%
Revenue
$0.01B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
$0.02
EPS Est.
$0.02
EPS Surpr.
+19.8%
Revenue
$0.21B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
$0.02
EPS Est.
$0.03
EPS Surpr.
-17.2%
Revenue
$0.22B
Q4 FY2024
Oct 23, 2024Miss
EPS Actual
$0.00
EPS Est.
$0.03
EPS Surpr.
-93.4%
Revenue
$0.26B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.47 | $0.47 | $0.47 | 1 |
| Q3 FY2026 | $0.54 | $0.54 | $0.54 | 1 |
| Q2 FY2026 | $0.56 | $0.56 | $0.56 | 1 |
| Q1 FY2026 | $0.46 | $0.46 | $0.46 | 1 |
| Q4 FY2025 | $0.39 | $0.39 | $0.39 | 1 |
| Q3 FY2025 | $0.52 | $0.52 | $0.52 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $4.3B | $4.3B | $4.3B | 1 |
| Q3 FY2026 | $4.2B | $4.2B | $4.2B | 1 |
| Q2 FY2026 | $4.2B | $4.2B | $4.2B | 1 |
| Q1 FY2026 | $4.2B | $4.2B | $4.2B | 1 |
| Q4 FY2025 | $4.0B | $4.2B | $4.4B | 2 |
| Q3 FY2025 | $4.4B | $4.6B | $4.8B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 22, 2026 | +6.5% | $1.08 | $1.08 | +0.00% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -17.9% | $1.00 | $1.00 | +0.00% |
| ▼ Q4 FY2025 | Oct 23, 2025 | -13.7% | $0.93 | $0.93 | +0.00% |
| ▼ Q3 FY2025 | Jul 22, 2025 | -96.3% | $1.09 | $1.09 | +0.00% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +19.8% | $1.22 | $1.24 | +1.64% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -17.2% | $1.43 | $1.43 | +0.00% |
| ▼ Q4 FY2024 | Oct 23, 2024 | -93.4% | $1.13 | $1.13 | +0.00% |
| ▼ Q3 FY2024 | Jul 24, 2024 | -91.3% | $0.98 | $0.98 | +0.00% |
Q2 FY2026+0.00%
Report Date
Apr 22, 2026
EPS Beat/Miss
+6.5%
Price Before
$1.08
Price After
$1.08
Q1 FY2026+0.00%
Report Date
Feb 25, 2026
EPS Beat/Miss
-17.9%
Price Before
$1.00
Price After
$1.00
Q4 FY2025+0.00%
Report Date
Oct 23, 2025
EPS Beat/Miss
-13.7%
Price Before
$0.93
Price After
$0.93
Q3 FY2025+0.00%
Report Date
Jul 22, 2025
EPS Beat/Miss
-96.3%
Price Before
$1.09
Price After
$1.09
Q2 FY2025+1.64%
Report Date
Apr 30, 2025
EPS Beat/Miss
+19.8%
Price Before
$1.22
Price After
$1.24
Q1 FY2025+0.00%
Report Date
Feb 27, 2025
EPS Beat/Miss
-17.2%
Price Before
$1.43
Price After
$1.43
Q4 FY2024+0.00%
Report Date
Oct 23, 2024
EPS Beat/Miss
-93.4%
Price Before
$1.13
Price After
$1.13
Q3 FY2024+0.00%
Report Date
Jul 24, 2024
EPS Beat/Miss
-91.3%
Price Before
$0.98
Price After
$0.98
Avg Beat Reaction+0.82%
Avg Miss Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move+1.64% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GNMLF ends December
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) most recently reported earnings on April 22, 2026 for Q2 FY2026, posting EPS of $0.03 — beating the analyst consensus of $0.03 by +6.5%. The next GNMLF earnings date is expected around September 1, 2026.
Each quarter, investors track GNMLF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GNMLF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GNMLF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GNMLF earnings · 5 questionsGenomma Lab Internacional, S.A.B. de C.V.'s next earnings report is expected around September 1, 2026. GNMLF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GNMLF historically reports after market close (AMC).
GNMLF earnings datewhen is GNMLF earningsGNMLF next earnings datewhen does GNMLF report earningsGNMLF earnings calendar
▸ Source: FMP · Genomma Lab Internacional, S.A.B. de C.V. SEC filings · US GAAP · Genomma Lab Internacional, S.A.B. de C.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026